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Introduction
Chemical methods exist that produce modified analogues of
natural proteins, precisely of the type that are made by recombi-
nant techniques: are these chemical approaches entitled to be
called 'protein engineering'? It seems important to pose this
question but, curiously, less important to give a definitive answer
to it. It is probably enough to note that the journal Protein Engin-
eering has sought to have protein-chemical mediods represented
on its Editorial Board, and that protein chemists working toward
the same goals as those using recombinant techniques are sub-
mitting papers to it in reasonable numbers. This seems to indicate
that whatever the final decision on terminology, should there ever
be one, the community of interest is already recognized.
A more interesting question is: what decides whether the chemi-
cal or the recombinant approach is best, and (most interesting
of all) what can the two approaches do together that neither can
do so well on their own? The present review addresses these
points, principally by reference to a few representative papers
published in the last three years, die period during which recom-
binant methods became comparable in their power with chemical
ones.
The choice of a paper for inclusion was governed by the wish
to be able to illustrate validly and concisely die principal exper-
imental issues involved. Thus, omission of a paper implies no
judgement whatever as to either priority or absolute value of the
research described.
The objective
Modern biology and medicine have produced a great demand
for proteins having novel structures, not found in nature. Many
of the purposes for which this is done have been well discussed,
in so far as they affect recombinant preparations, in a previous
review in this journal (Leatherbarrow and Fersht, 1986), and the
same ideas apply when it is chemical methods that are contem-
plated. Analogues are invaluable for study of structure-activity
relationships, and where questions arise of the importance of non-
covalent interactions in protein structure and function. Further-
more, existing knowledge of the underlying principles of protein
action makes it possible to design analogues with tailored func-
tional properties. Additionally, the study of a protein in its true
biological setting (organ, tissue or cell) often calls for an analogue
modified by isotopic substitution, or by a fluorescent chromo-
phore, or by some magnetic-resonance reporter group.
The choice of methods
One does not make an analogue simply to be able to say one
has done so: it is necessary to be able to make the wanted products
in acceptable quantity and quality for use in the proposed ex-
periment. The preparation should consume as lirde time and
resources as possible.
When the production of the analogue involves no more than
substitutions between coded ammo acids, it should now be as-
sumed that this will normally be done by recombinant methods
or (an approach that sometimes seems in danger of being forgot-
ten) traditional mutagenesis and selection techniques. On the other
hand some very interesting substitutions involve artificial, non-
coded amino acids, or their analogues. Although it is possible
to envisage ways in which recombinant methods could be made
to work even here (e.g. see Offord, 1980), they are not at present
a particularly practical proposition. In addition to substitutions
that go outside the genetic code, there is a further area in which
chemical methods are strong where recombinant mediods are
sometimes weak; the production of relatively short polypeptides.
Also, certain substitutions of coded amino acids are now so simple
by chemical methods that they represent a route equally as at-
tractive as recombinant methods.
It should, for example, be remembered that human insulin,
the production of which was seen as the first real test of recom-
binant methodology, was in fact first brought to die market in
any quantity by the use of semisyndietic, i.e. chemical, metfiods.
This was not a question of historical inertia, since the development
of the semisynthetic methods involved did not begin in any serious
way until after the start of the recombinant work. Inspection of
the recent literature (see below) suggests that this is by no means
an isolated example of the way in which chemical methods will
continue to complement recombinant ones.
Chemical approaches
The choice lies between total synthesis, semisynthesis and die
chemical modification of side chains.
Total synthesis
Total synthesis, as has already been said, is the mediod of choice
for small polypeptides. One of the two main variants, die so-
called stepwise or solid-phase mediod, has been so greatly im-
proved in recent years diat it is now wiuiin the reach of any
molecular biology laboratory diat can afford die equipment. On
die odier hand, only the most expert laboratory could contemplate
undertaking die alternative route, known as fragment conden-
sation. Fragment condensation involves die classical organic-
chemical synmesis of die peptide by the condensation in free
solution, first of die amino acids to form a number of longer
fragments of die wanted sequence, and dien die successive con-
densation of die resulting fragments to form ever larger stretches
of die target sequence until die complete molecule is obtained.
The solid-phase method, as is widely known, proceeds by
anchoring die C-terminal residue to a resin. The amino acids are
added in successive cycles of reaction, in reverse order to die
normal direction for reading a sequence. The details of how this
is done vary from one laboratory to anomer, but all variants of
the technique have in common die need to ensure diat die ef-
ficiency of incorporation of the new amino acid (the 'coupling
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efficiency') is as near 100% as possible. For a target product
of n residues, and assuming a constant coupling efficiency of
r% per cycle, the proportion of molecules of the wanted product
in the final mixture is (r/100)""1 X 100%. If r is 98% (already
a relatively impressive figure by the standards of general organic
synthesis), then the proportion of correct molecules in a product
of 100 residues is 13% and that in a product of 300 residues is
0.24%. It suffices for the average efficiency per cycle to fall to
95 % for these two numbers to become 0.62% (100 residues) and
0.00002% (300 residues). Much attention has therefore been
devoted to keeping the coupling efficiency as high as possible.
Other recent developments have to do with a different choice
of protecting groups and solid-phase resins from that made when
the method was originally proposed.
Given access to one of the modern automated machines exploit-
ing this chemistry, few workers should hesitate in synthesising
a product of, say, 30 residues. For most syntheses, it is hard
to imagine any other method, chemical or recombinant, being
able to compete. Most non-coded amino acids (including the D-
amino acids) can be incorporated at will by this method.
Literally thousands of analogues of polypeptides have been
made by one or other variant of these methods; they have pro-
vided much of our current understanding of the biology of shorter
peptides, and this situation is unlikely to change in the near future.
An overview of what is possible can be obtained by reading any
of the recent volumes of either the European or the American
Peptide Symposia (e.g. Ragnarsson, 1984; Deber et al., 1985).
Side-chain modification
Space does not permit a discussion of the other major method
of protein alteration, side-chain modification without peptide-bond
cleavage or synthesis. None the less, this approach, to which
we owe much of our present understanding of structure—activity
relationships, will continue to give us much information, particu-
larly if one can attempt the specific conversion of just one side-
chain, rather than affecting simultaneously many side-chains of
the same type. While mentioning the classical experiment of con-
version of a serine protease to a cysteine one (Neet and Koshland,
1966; Polgar and Bender, 1966) we should not forget the remark-
able advance in specific side-chain conversion reported by Kaiser
and Lawrence (1984). As an illustration of a general approach
to the production of semisynthetic 'chemical mutations' at the
catalytic centres of enzymes, these authors converted papain into
a highly efficient oxido-reductase, by means of a series of reac-
tions designed in the light of existing knowledge of structure-
activity relationships.
semisynthesis
This approach combines that of total chemical synthesis with more
biologically oriented methods. In it, fragments of naturally occur-
ring proteins are used as ready-made intermediates for the chemi-
cal synthesis of proteins. Only the part of the molecule that is
to be changed (often just a single residue) need be synthetic In
principle, this method has the considerable advantage over total
synthesis that most analogues currently required are 99% or more
of native structure. The synthesis of these portions can be left
to the biosynthetic machinery while one concentrates on the 1 %
or less into which one wishes to introduce a change. The semisyn-
thetic approach has the advantage over recombinant methods that
it is just as easy to incorporate non-coded amino acids as it is
to incorporate coded ones. Its limitation as a method derives from
the necessity of finding a degradation method (enzyme or
chemical reagent) that not only cleaves the protein into a reason-
ably small number of fragments, but also exposes the site that
it is wished to modify. A few of the same problems of side-chain
protection arise that are encountered with total synthesis. How-
ever, the use of proteolytic enzymes working in reverse as
coupling agents (see below) has greatly simplified this problem.
The methodology of the several variants of protein semisynthesis
has been extensively reviewed (e.g. Offord, 1980; Sheppard,
1979; Chaiken, 1981).
If total synthesis helped us learn most of what we know about
smaller peptides, it seems to be the message of the tables and
the papers cited below that semisynthesis has contributed a con-
siderable amount to work on larger molecules, where few if any
totally synthetic analogues are available. There is no sign of these
developments slackening off.
Table I summarizes the principal types of protein semisynthesis.
Because of limitation of space, the rest of this review will con-
centrate principally on semisynthesis via the formation of pep-
tide bonds.
The main experimental requirements that confront us are: (i)
a means of efficient cleavage at a few specific sites; (ii) a means
for separating the fragments; (iii) a means of ensuring that the
fragments, when coupled back together, will combine only
through their a carboxyl and amino groups; (iv) a set of reagents
and procedures that enable all steps to be carried out under con-
ditions mild enough to avoid permanently compromising the
chemical and three-dimensional structure of the product.
The first two of these requirements have been met simply by
drawing on the techniques developed by workers in the field of
protein sequencing. The third requirement (to ensure coupling
through the correct groups) can be met by careful selection from
Table I. The principal lands of protein semisynthesis
Type Description Applied to.
1. Non-covalent The formation of functioning complexes of protein fragments One or more of
the fragments can be replaced by a synthetic or modified version
Pancreatic nbonuclease1, 5 aureus nuclease2,
cytochrome c3, thioredoxin4, somatotropin3,
phospholipase A26, myoglobin7,
IgA fragment F v 8
Insulin9, antibodies10
See Tables H and III
2 Covalent
(l) via - S - S — bridges The reoxidation of reduced chains of a multichain protein, one of the chains
having been replaced by a synthetic or modified version
(u) via the peptide bond The chemical coupling, via alpha amino and carboxyl groups, of fragments of
natural sequence with those of altered sequence. The altered sequences can be
obtained by total synthesis or by semisynthesis, or by any other method
References (including reviews). 1, Richards (1958), 2, Taruuchi a al (1967), 3, Harris and Offord (1977); 4, Slaby and Holmgren (1975), 5, Li et al
(1978); 6, Kihara et at (1981), 7, Hagenmaier et al (1978), 8, Gavish et al (1978), 9, Zahn a al (1981); 10, Rosenberg and Terry (1977)
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the available techniques of the classical methodology of protein
synthesis to bring about differential protection of side-chains.
Alternatively, correct coupling can now be ensured with little
or no protection by using the specificity of proteolytic enzymes
acting in reverse (Laskowski, 1978; Inouye et al., 1979; Mar-
kussen, 1981). This development, which had been impatiently
awaited for many years, is not restricted to small substrates: it
has even been applied with success to human growth hormone
(Graf and Li, 1981) and other protein examples are given below.
This advance has completely revolutionized the field: many
of the more difficult protection strategies used until recently
(Offord, 1980) are now needed only under very special circum-
stances. Ligation by proteases is one of the major factors respon-
sible for semisynthesis having remained competitive in some
fields with recombinant methods, even when substitutions by
coded amino acids are involved.
The power of the ligation method has recently been improved
by using proteases to couple, to the C termini of appropriate
fragments, not peptides, but aminoacyl active esters (Rose et al.,
1987). Remarkably enough, conditions can be found under which
some aminoacyl active esters neither polymerize through their
own free a-amino groups, nor acylate the side-chain amino
groups of the substrate or the hgatmg protease. Polypeptide ac-
tive esters resulting from this operation have proved particular-
ly useful in ligating the nicked peptide bonds in non-covalent
complexes of fragments of cytochrome c (Wallace and Proud-
foot, 1987; K. Rose, private communication; and see below).
Table D. Some earlier examples of fragment-condensation syntheses
Protein Principal operations earned out
Insulin Enzyrruc and chemical recoupluig of sequences from the
last eight residues of the B-chain (residues important in
receptor binding, residues implicated in activity by
studies on mutant human insulins)"12 '3
Proinsulin Modified open-chain form by combining natural chains
with a short synthetic bridge14
Ferredoxui Preparation of analogue free of aromatic residues for
functional and physical studies of iron-sulphur
clusters1112'14
Nucleases Production of analogues of intact protein by chemical or
enzymic reforming of nicked peptide bond in non-
covalent complexes'4
Cytochrome c Recombination of CNBr fragments Several analogues
made for activity, lmmunological and physical studies
(e g Tyr67 changed to p-fluorophenylalanine). Side-
chain-specific reactions on separated fragments before
reconstructing the protein (gives proteins modified on
only some of the side-chains susceptible to the reagent
in question)"12 '5
Myogtobin Coupling of two synthetic and one natural fragment to
give the whole sequence16
Protease inhibitors Insertion of new residues at the protease-sensitive site
Includes the production by design of new biological
specificities"''4
Phospholipase A2 Coupling of short peptides to a large natural fragment
Many analogues for activity and physical studies
including substituuon by nor-leucine"-l2>17
References (including reviews) 11, Offord (1980), 12, Sheppard (1979),
13, Riemen a al. (1983), 14, Chaiken (1981), 15, Wallace and Rose
(1983); 16, Simmerman a al. (1982), 17, van Scharrenburg a al (1983,
1984)
The fourth requirement (mild reagents and solvents) was met
by trial and error. We now know that many chemical substances
that would have been expected to destroy protein activity will
not do so, whilst certain others, apparently much milder, are fatal
in their effects (see, for example, Offord, 1980).
That the origins of the method lie in primary structure deter-
minations becomes obvious when we look a little closer. Thus,
fragment-condensation semisynthesis combines Sanger's original
strategy of sequencing (with the additional option of CNBr cleav-
age) with that of classical solution synthesis. Stepwise semisyn-
thesis combines the strategy of Edman (or that of sequencing by
carboxypeptidase digestion) with that of conventional stepwise
synthesis.
Tables II and HI give a general summary of the fields to which
the two methods have been applied, together with selected refer-
ences to earlier reports and reviews, semisynthetic work pub-
lished in the last three years is reviewed in the text, according
to the principles of selection stated above.
Recent advances in semisynthesis
Insulin. Insulin has for a long time been an excellent example
of the fruitful combination of knowledge obtained by study of
analogues and derivatives obtained by all possible methods. Ex-
tensive studies have been carried out on hundreds of analogues,
both synthetic and semisynthetic, on side-chain derivatives, and
on evolutionary variants. These results have combined with data
from X-ray and other physical methods to tell us a great deal
about the structural basis for the action of this hormone, and about
its co-operativity. semisynthetic analogues, which are very easy
to make by what are practically standardized methods, continue
to play their role. Only representative examples can be given
here, restricted to the last three years.
Fragment-condensation semisynthesis has been used to probe
the role of the region B24-B25-B26. Kobayashi et al. (1984)
studied [SerB24]insulin and [Ser325]insulin in terms of receptor
binding, negative co-operanvity and immunoreactivity. Shoelson
et al. (1984) tested the biological activity and pharmacokinetic
properties of semisynthetic [SerB24]insulin in dogs. They discuss
the abnormal clearance of the analogue in vivo, and the causes
of hyperinsulinaemia in both diabetic and non-diabetic individuals
who secrete this abnormal insulin. Haneda et al. (1985), conti-
nuing the studies of Kobayashi et al. (1984), carried out further
tests on the potency of the same two serine analogues, which
they extended to the investigation of the rates of their degrada-
tion. Degradation is slower than for the native sequence, and the
Table TB. Some earlier examples of stepwise syntheses
Protein Principal operations earned out
Insulin Very many analogues with normal amino acids In
addition, introduction of I3C, of D-amino acids in sites
critical for activity, selective tnation, selective todinauon.
Conversion of porcine insulin into human insulin"-12
Ferredoxin Numerous analogues for activity and physical studies of
the iron-sulphur clusters"-'2
Phospholipase A2 Many substitutions for physical and activity studies.
Introduction of /3-alanine and I3C amino acids (both D
and L ) ' 7 ' 8
Glucagon Substitutions for physical and activity studies"
References (including reviews): 18, Offord and Di Bello (1978);
19, Flanders et al (1984) Other refs, see footnote to Table II.
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authors discuss the pharmacokinetic implications of this finding.
These analogues could also have been made by recombinant
methods: in the event it proved more convenient to do so by
semisynthesis.
Nakagawa and Tager (1986) have described a magnificent
series of analogues in this same region of the molecule, many
of which could not have been made by existing recombinant tech-
niques. These consist of: (i) forms of the hormone in which 5,
6 or 7 residues have been deleted from the C terminus of the
B-chain; (ii) analogues in which Phe825 has been replaced by
natural or unnatural amino acid residues; and (iii) analogues lack-
ing the C-terminal five residues of the B-chain and in which
Phe825 has been replaced by a-carboxaminated amino acids.
Among the unnatural amino acids used were naphyl-(l)-alanine,
naphyl-(2)-alanine, and homophenylalarune. These were of par-
ticular interest because of the different bulk of their side-chain
relative to that of phenylalanine itself. Among the many con-
clusions drawn from the experiments carried out on these ana-
logues there is only room to mention here the proposal that steric
hindrance involving the C-terminal domain of the B-chain plays
a major role in directing the interaction of the hormone with its
receptor.
Degradation of insulin at the target cell is an important adjunct
to the expression of the biological activity of the hormone. In
the author's laboratory we have produced a number of mono-iso-
typically labelled insulins in order to be able to characterize better
the products of insulin degradation under various conditions:
[3H-PheB1]insulin (Halban and Offord, 1975); ^H-Gl/'jinsulin
(Davies and Offord, 1985); ['^B29]insulin (Rose et al., 1984);
pH-Gly^1]insulin (L.A.Savoy and K.Rose, unpublished results);
and pH-AUOinsuhn (C.Bradshaw, J.G.Davies, R.E.Offord
and K.Rose, unpublished results). These analogues have been
shown to behave authentically in a variety of systems. The degra-
dation products liberated from them under various conditions have
been identified either by radiochemical sequencing (e.g. Muir
et al., 1986; Davies et al., 1986) or mass spectrometry (Rose
et al., 1984; K.Rose and L.A.Savoy, unpublished data). It has,
for example, been possible to identify with some confidence the
sites of cleavage of the hormone by the enzyme insulin proteinase.
This enzyme may be responsible for insulin degradation in intact
tissues (Duckworth and Kitabchi, 1981). The results obtained
using the senusynthetic analogues, when taken into account with
those from studies in cells, organs and the whole animal, do
indeed offer some support for the physiological significance of
this enzyme. The possible secondary biological activities of the
fragments liberated by the enzyme (which as a result of the above
work have been well characterized as regards their structure and
purification) therefore merit further study.
The 50 or so papers devoted to the clinical behaviour of
semisynthetic human insulin are outside the scope of this review.
Cytochrome c. This protein lends itself particularly well to the
fragment-condensation version of the semisynthetic method. Two
of the most reliable cleavage agents, trypsin and CNBr, have
their points of attack at convenient positions. Additionally, several
instances are known of the non-covalent association of large
fragments to form active complexes.
The earlier work having already been reviewed (Offord, 1983,
and the references cited therein), only more recent advances will
be mentioned.
Ten Kortenaar et al. (1985) have used the fragment-conden-
sation approach to prepare a number of analogues, including
[fluoroPhe67]cytochrome c, [Val^Jcytochrome c, [Leu^cyto-
chrome c and [Tyr^cytochrome c. Following the earlier work
of this group on n.m.r. of such analogues, the paper in question
concentrates principally on the measurements of the redox poten-
tials of the analogues produced, and the implications of the results
obtained for the mechanism of electron transfer by this protein.
In the author's own laboratory, the most recent of the many
publications of C.J.A.Wallace and co-workers on the subject
(Wallace and Proudfoot, 1987) reports the preparation of a cyto-
chrome c analogue from which the so-called 'bottom loop' of
the native structure had been excised. As pointed out by
Leszczynski and Rose (1986), this loop (residues 40-55) is one
of the principal differences between mitochondrial cytochrome
c and the bacterial cytochrome c55S, and may account for the
differences in functional properties between the two proteins. The
loop is a relatively self-contained structure, with its N-terminal
and C-terminal portions in close proximity. Wallace and Proud-
food (1987) were therefore easily able to produce a semisynthetic
cytochrome c analogue that lacked it, chemically coupling the
appropriate fragments of the native protein by means of the
enzyme-directed, active-ester method mentioned previously. They
have characterized the biological properties of their product and
have commented on the original hypothesis of Leszczynski and
Rose.
Proudfoot et al. (1986) have prepared a semisynthetic analogue
of fully acetimidylated horse cytochrome c in which the peptide
chain is nicked between residues Gly37 and Arg38. In contrast
with a complex previously described (Harris and Offord, 1977),
in which the break in continuity was between residues Arg38 and
Lys39, the new analogue had a nearly normal redox potential
and could more fully restore succinate oxidation to mitochondria
depleted of cytochrome c. Studies of this and other semisynthetic
analogues led the authors to propose a structural reason for the
lower biological activity of the earlier complex, and they put
forward an explanation for the evolutionary in variance of Arg38.
Wallace et al. (1986) have made and characterized some
semisynthetic chimeras of cytochrome c (horse-yeast,
cow—yeast). Their results permit a number of deductions about
the nature of the haem crevice.
Wallace and Corthdsy (1986) have replaced residue Glu66 of
horse cytochrome c with nor-valine, glutamine and lysine. As
a necessary control they put back by the same means the authen-
tic residue, glutarruc acid. Residue Glu66, which is quite strongly
conserved in cytochrome c, forms part of a cluster of acidic
residues that occurs in all cytochromes c but whose function is
obscure. Comparative studies of the analogues mentioned above
suggest that Glu66 contributes significantly to the stabilization of
the active conformation of the protein, probably by salt-bndge
formation, and it appears to participate in the redox-state-depen-
dent binding site for ATP. The results support the idea that the
charged surface residues in cytochrome c influence redox poten-
tial through the field intensity experienced at the redox centre,
while they affect the kinetics of electron transfer through the
dipole moment that they generate.
Veloso et al. (1984) wished to investigate the part of the apo-
cytochrome c molecule that is recognized by cytochrome c syn-
thetase. They prepared, by solid-phase synthesis, tritium-labelled
fragment (1 -25), as well as the same fragment in which the two
cysteine residues had been replaced by glycine. On incubation
of these fragments with the enzyme, and with hemin, the authentic
sequence, but not the analogue, combined with the hemin and
cytochrome fragment (23-104) to give a semisynthetic non-
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covalent complex of the cytochrome. This product had properties
practically indistinguishable from that of the complex of entirely
natural origin. The authors draw from their observations certain
conclusions concerning the recognition of the apocytochrome by
the enzyme.
Myoglobin. Continuing their series of myoglobin analogues modi-
fied at or near the amino terminus, Busch et al. (1985) have used
stepwise methods to prepare a number of semisynthetic analogues
enriched with I3C at position 1. The replacements include I3C
Gly, Ala, Val, Leu and He. After extensive characterization, the
analogues were used in a number of n.m.r. experiments. The
results elucidated the nature of the interaction between the side-
chain of residue 1 with the invariant hydrophobic cluster Leu2,
Leu137, and the effect that this cluster exerts on the hydration
volume available to the alpha amino group.
Haemoglobin S. Seetharam and Acharya (1986) have found a
fragment-condensation method for resealing the nick in a non-
covlent complex of fragments of the a-subunit of haemoglobin
S. The way is now open for the production of analogues of the
a-chain.
Precursor of oxytocin-bovine neurophysin I. A semisynthetic
precursor, of 105 residues in length, was obtained (Kanmera and
Chaiken, 1985) by coupling a synthetic oxytocinyl peptide to
native neurophysin. The precursor contained the full polypeptide
sequence deduced from the corresponding DNA except for omis-
sion of the C-terminal histidine residue. Kanmera and Chaiken
studied the binding of their product to various immobilized lig-
ands, as well as the resistance of the disulphide bridge to reduc-
tion. The results led them to deduce that the precursor
self-associates, and that the ligand-binding site of the neurophysin
domain is occupied intramolecularly by the hormone domain.
They conclude that both the self-association surface and hormone-
binding site are established during the initial folding-up of the
precursor, and that the general structure of the precursor is estab-
lished before enzymic processing liberates mature hormone and
neurophysin.
Glucagon. semisynthetic work continues on this peptide which,
in spite of its small size, tends to be intractable by virtue of its
unfavourable solubility properties. Flanders et al. (1984) have
reported the production of stepwise semisynthesis of [Phe1] and
[Ala1] analogues. Studies on these analogues, taken together
with those on the des-Uisx glucagon produced en route, indicate
that the a-amino group is involved more in signal transduction
than in binding, but that the aromatic nature of the side-chain
of His1, and its hydrogen-bonding capacity, are important for
both binding and transduction. In addition, circular dichroism
studies gave evidence for unexpected conformational changes
throughout the structure of the analogues, possibly having rel-
evance for function—activity relationships.
Nucleases and pancreatic phospholipase A2. Like some of the
other proteins mentioned, these enzymes have a long history of
intensive study by all available means; only recent, representative
work is mentioned here.
Sasakin et al. (1985) and Stern and Doscher (1986) have
studied structure —function relationships in bovine pancreatic
ribonuclease, the latter publication demonstrating conclusively
a role for Asp121 in the catalytic site. Taylor et al. (1985) de-
signed an analogue of ribonculease S on the basis of existing
knowledge of structure—activity relationships, and then prepared
it by the non-covalent variant of semisynthesis. The analogue
had the predicted properties.
The group of Slotboom and de Haas have for a long time used
semisynthetic analogues of pancreatic phospholipase A2 to study
various aspects of structure—activity relationships, including the
differential response of the enzyme to the various types of
lipid—water interface that it encounters, an essential feature of
the control of its activity (see references in Tables II and IE).
To this end, they have introduced, as well as coded amino acids,
many non-coded and isotopically substituted residues. Their more
recent work is described in van Scharrenburg et al. (1984) and
Jain et al. (1986).
Antibodies. Chang et al. (1985) have made some interesting
observations on the selectivity of proteolytic cleavage of anti-
body light chains at the regions joining variable with constant
regions, which they propose to use for chemical semisynthesis
of human-mouse light-chain chimeras. If this proves easy to
do, it might constitute a useful adjunct to recombinant techniques.
Protease inhibitors. In a recent study, Tschesche et al. (1987)
prepared and characterized 10 analogues of aprotinin, the Kunitz
trypsin inhibitor from bovine mast cells. As is well known, this
inhibitor functions by engaging the active site of the protease in
an abortive (or extremely slow) cleavage of a particular peptide
bond (Tschesche and Kupfer, 1976; cf. Laskowski and Kato,
1980, and references cited in these publications). The bond in
question is that between residues 15 and 16 of the inhibitor. Much
of the specificity of this interaction depends on the side-chain
of residue 15, which is a lysine in the natural inhibitor. Previous
methods of producing analogues of inhibitors of this type have
involved enzymically catalysed insertion of the new residue (e.g.
Sealock and Laskowski, 1969), or a variety of chemical pro-
cedures (e.g. Jering and Tschesche, 1976; cf. Kowalski, 1978).
Recombinant methods have also been used to prepare four ana-
logues of approteinase inhibitor at the corresponding key site
(Rosenberg etal., 1984; Courtney et al., 1985; Matheson etal.,
1986) in that inhibitor. These alterations, naturally enough, were
limited to exchanges between natural, coded amino acids.
In the study mentioned above (Tschesche et al., 1987), there
is no limitation either to coded amino acids, or to those able to
participate in enzymically catalysed insertion. The key bond,
Lys15 —Ala16, was first split by an enzyme less susceptible than
trypsin to the inhibiting action of aprotinin, or by rendering this
peptide bond susceptible to fast tryptic cleavage by selective
cleavage of the neighbouring Cys^-Cys38 disulphide bond (Jer-
ing and Tschesche, 1976), and then all the side-chain carboxyl
groups of the protein were protected by esterification so that they
could not participate in any of the subsequent steps.
Although it was unavoidable that the newly liberated carboxyl
group of residue Lys15 was esterified as well, it could be selec-
tively deprotected by using a protease as a specific esterase. Car-
boxypeptidase B then removed the lysine, leaving the carboxyl
group of the residue Cys14 as the only free one in the whole
molecule. Appropriate derivatives of new amino acids were
attached to this uniquely reactive group by a variety of the con-
ventional techniques of protein semisynthesis, whilst the closure
of the peptide bond between residues 15 and 16 was accomplished
either by chemical or enzymic coupling.
The substitutions that were carried out involve the replacement
of the -(CH^—NH2 of the lysine side-chain by a range of
neutral groups of different size and degree of branching. In some
instances this involved replacement of the lysine by coded amino
acids (Gly, Ala, Val, Leu, De), whilst in others the replacement
was by non-coded ones [side-chains —CH2CH3, —(CH2)2CH3,
j , -C(CH3)3, -CH2C(CH3)3]. The spectrum of
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proteases inhibited by these analogues differs radically from one
analogue to the other. Quite new biological specificities are
created, and the theoretical and practical implications are dis-
cussed by the authors (Tschesche et al., 1987). The processes
involved in producing these analogues seem no more complex
than the various steps of the corresponding recombinant methods
(in those cases in which they can be applied, i.e. to coded amino
acids). There is also no problem of expression, refolding, or the
formation of the correct disulphide bridges, as there would be
with recombinant products. Yields are reasonable and the methods
lend themselves to scaling up.
Bode et al. (1984) have reported the refined 2.2 A X-ray
crystal structure of the ternary complex formed by bovine trypsin-
ogen, Val—Val, and semisynthetic [Arg15] bovine pancreatic
trypsin inhibitor. The inhibitor analogue was obtained by enzyme-
catalysed fragment-condensation. Replacement of the reactive site
Lys by an arginine residue is accompanied in the complex by
small movements within the specificity pocket of polar side-chains
belonging to trypsinogen. Solvent molecules, also, are moved.
It was possible to detect the expulsion from the pocket of a
specific water molecule, which allowed the bulkier guanadinyl
group to approach the carboxylate group of Asp189 of the tryp-
sinogen.
Conclusion
As far as the relative merits of different approaches are con-
cerned, the facts should be left to speak for themselves. In science
it is generally true that no one method is universally applicable.
Many laboratories (including the author's own) already use both
chemical and recombinant methods, as appropriate. This trend
is likely to continue, and it is very much to be hoped that the
present prospect, of the two approaches complementing each
other in an ever more powerful way, will in fact be realized.
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